The short version of 研究代号 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
British observers believed the war to be all but over after the capture of the two capitals. However, the Boers had earlier met at the temporary new capital of the Orange Free State, Kroonstad, and planned a guerrilla campaign to hit the British supply and communication lines. The first engagement of this new form of warfare was at Sanna's Post on 31 March where 1,500 Boers under the command of Christiaan de Wet attacked Bloemfontein's waterworks about 37 kilometres (23 mi) east of the city, and ambushed a heavily escorted convoy, which caused 155 British casualties and the capture of seven guns, 117 wagons, and 428 British troops. After the fall of Pretoria, one of the last formal battles was at Diamond Hill on 11–12 June, where Roberts attempted to drive the remnants of the Boer field army under Botha beyond striking distance of Pretoria. Although Roberts drove the Boers from the hill, Botha did not regard it as a defeat, for he inflicted 162 casualties on the British while suffering only around 50 casualties.
== Ethical concerns == Advancements in recombinant DNA technology have revolutionized the idea of treating diseases through the reconstruction or replacement of faulty genes. Gene therapy is a technique that transplants normal genes into cells that contain missing or defective genes to correct genetic disorders. Nevertheless, several concerns have been raised about the efficacy of gene therapy due to its limited success rate in clinical trials. Over the years, immense efforts have been placed to fully understand vectors, viruses, and their communication with their host's immune system. However, not every defense system reacts the same. Some patients have experienced an "autoimmune-like" response where their body rejects this treatment. The heterologous genes are recognized as foreign to the host and can induce cytokine-mediated inflammatory responses that are ultimately destroyed by their cytotoxic T-cells. This has called into question the relationship between vector dosage and cellular toxicity as scientists recognize that inappropriate activation of these responses can cause severe side effects not only to the disease-infected cells but other healthy parts of the body. Genetic modification used to address concerns outside of medical necessities such as eye color, athletic abilities, intelligence, etc. is one example that has brought into question the ethicality of its purpose. Eugenics, which places a group of desirable human characteristics over another has led to fears of potential backlash toward genetically modified, or genetically unmodified individuals in society.
Hypertrichosis (hirsutism) produces a long, thick, wavy coat that often has delayed shedding or fails to shed completely, and may lighten in color. Hirsutism has been suggested to be pathognomonic for PPID, with up to 95% of horses having PPID. Laminitis Increased drinking and increased urination Pot-bellied appearance Weight loss Redistribution of fat, leading to bulging supraorbital fat pad, a "cresty" neck, and fat over the tail head or in the sheath of males Lethargy Behavioral changes, often an increased docility Muscle wasting, especially along the top line Increased sweating, or less commonly, decreased sweating Increased appetite Decreased sensitivity to pain Recurrent infections due to immune impairment Rarely neurologic signs such as narcolepsy, blindness, or seizures Suspensary ligament degeneration
Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide. These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety. Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP. Only the crystal structure of Y1 in complex with two antagonist is available.
Much to the dismay of comedy club owners booking him, he began abandoning trademark celebrity impressions, opting instead to try adding observational and character humor to his comedic repertoire, a process that often involved forcing himself to improvise and scramble in front of dissatisfied live audiences that came to see him do impressions. From 1990 to 1994, Carrey was a regular cast member of the ensemble comedy television series In Living Color. The popularity of the series helped him to land his first few major film roles.
Sources: en.wikipedia.org
== Research and career == Dunn-Walters has over a hundred primary research publications. She studies B cell development in disease, and how the immune system changes during ageing. She has developed new characterisation techniques to understand immune responses, including single-cell and repertoire approaches. She discovered IgM memory B cells in the spleen, that the older immune system has a less diverse repertoire of B cells, that there are at least 10 different types of B cells, that different types of B cells may have different repertoires and therefore be responding to different stimuli. She works in collaboration with computer scientists and together they have produced online tools for repertoire analysis. More recently, the development of new tools for distinguishing between productive and sterile transcripts of Ig constant region genes in B cells has shown that B cells become primed for Immunoglobulin class switching in a stage before they actually switch. She is part of the CARINA (Catalyst Reducing Immune Ageing) Network, a collective which looks to understand how ageing impacts the immune system and vice versa. Dunn-Walters has served on grants awarding and strategy committees for funding bodies such as the UK Research and Innovation (UKRI) MRC and BBSRC, Research Council of Norway, Fondazione Cariplo Italy. She is a member of the British Society for Research on Ageing where she has previously served on the board and as Programme Secretary.
National Ignition Facility: This 192-beam, stadium-size laser system is used to compress fusion targets to conditions required for thermonuclear burn. Experiments at NIF study physical processes at conditions that exist only in the interior of stars and in exploding nuclear weapons (see National Ignition Facility and photon science). Superblock: This unique high-security facility houses modern equipment for research and engineering testing of nuclear materials and is the place where plutonium expertise is developed, nurtured, and applied. Research on highly enriched uranium also is performed here. Livermore Computing Complex: One of the world’s most dominant high performance computing centers, the Livermore Computing Complex comprises several buildings that house many HPC systems that hold top-ranking positions on the Top500 list. LLNL is also home to the world’s largest Spectra TFinity tape library. The complex has nearly 48,000 square feet of machine floor space, supporting both classified and unclassified national security programs. In 2023, LLNL modernized the complex with upgrades to its power and water-cooling capacity. Titan Laser: Titan is a combined nanosecond-long pulse and ultrashort-pulse (subpicosecond) laser, with hundreds of joules of energy in each beam. This petawatt-class laser is used for a range of high-energy density physics experiments, including the science of fast ignition for inertial confinement fusion energy.
In Brazil, the Aeronautical Accidents Investigation and Prevention Center (CENIPA) was established under the auspices of the Aeronautical Accident Investigation and Prevention Center, a Military Organization of the Brazilian Air Force (FAB). The organization is responsible for the activities of aircraft accident prevention, and investigation of civil and military aviation occurrences. Formed in 1971, and in accordance with international standards, CENIPA represented a new philosophy: investigations are conducted with the sole purpose of promoting the "prevention of aeronautical accidents". In Canada, the Transportation Safety Board of Canada (TSB), is an independent agency responsible for the advancement of transportation safety through the investigation and reporting of accident and incident occurrences in all prevalent Canadian modes of transportation – marine, air, rail and pipeline. In China, the Civil Aviation Administration of China (CAAC) is solely responsible for all air investigations and safety inside the country after the split from the formal CAAC Airlines.
Natural calcium is a mixture of five stable isotopes—40Ca, 42Ca, 43Ca, 44Ca, and 46Ca—and 48Ca, whose half-life of 4.3 × 1019 years is so long that it can be considered stable for all practical purposes. Calcium is the first (lightest) element to have six naturally occurring isotopes. By far the most common isotope is 40Ca, which makes up 96.941% of natural calcium. It is produced in the silicon-burning process from fusion of alpha particles and is the heaviest stable nuclide with equal proton and neutron numbers; its occurrence is also supplemented slowly by the decay of primordial 40K. Adding another alpha particle leads to unstable 44Ti, which decays via two successive electron captures to stable 44Ca; this makes up 2.806% of natural calcium and is the second-most common isotope. The other four natural isotopes, 42, 43, 46, 48Ca, are significantly rarer, each comprising less than 1% of natural calcium. The four lighter isotopes are mainly products of oxygen-burning and silicon-burning, leaving the two heavier ones to be produced via neutron capture. 46Ca is mostly produced in a "hot" s-process, as its formation requires a rather high neutron flux to allow short-lived 45Ca to capture a neutron. 48Ca is produced by electron capture in the r-process in type Ia supernovae, where high neutron excess and low enough entropy ensures its survival. 46Ca and 48Ca are the first "classically stable" nuclides with a 6-neutron or 8-neutron excess respectively.
Sources: en.wikipedia.org
According to the NY-AG, only about 20% of the herbal supplements tested contained the plants claimed. The methodology used by the NY-AG was disputed. The test involves looking for DNA fragments from the plants named as the dietary supplement ingredients in the products. One scientist said that it was possible that the extraction process used to create the supplements removed or destroyed all DNA. This, however, would not explain the presence of DNA from plants such as rice or wheat, that were not listed as ingredients. A study of dietary supplements sold between 2007 and 2016 identified 776 that contained unlisted pharmaceutical drugs, many of which could interact with other medications and lead to hospitalization. 86% of the adulterated supplements were marketed for weight loss and sexual performance, with many containing prescription erectile dysfunction medication. Muscle building supplements were contaminated with anabolic steroids that can lead to health complications affecting the kidney, the heart, and cause gynecomastia. Multiple bodybuilding products also contained antidepressants and antihistamines. Despite these findings, fewer than half of the adulterated supplements were recalled.
=== Tangential trapezoid === If the incircle is tangent to the sides AB and CD at W and Y respectively, then a tangential quadrilateral ABCD is also a trapezoid with parallel sides AB and CD if and only if
== Disease relevance == Diseases have been linked to R5P imbalances in cells. Cancers and tumors show upregulated production of R5P correlated to increased RNA and DNA synthesis. Ribose 5-phosphate isomerase deficiency, the rarest disease in the world, is also linked to an imbalance of R5P. Although the molecular pathology of the disease is poorly understood, hypotheses included decreased RNA synthesis. Another disease linked to R5P is gout. Higher levels of G6P lead to a buildup of glycolytic intermediates, that are diverted to R5P production. R5P converts to PRPP, which forces an overproduction of purines, leading to uric acid build up. Accumulation of PRPP is found in Lesch-Nyhan Syndrome. The build up is caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which leads to decreased nucleotide synthesis and an increase of uric acid production. Superactivity in PRPS1, the enzyme that catalyzes the R5P to PRPP, has also been linked to gout, as well as neurodevelopmental impairment and sensorineural deafness.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。